Kidney TransplantationPhase 2/3NCT00425698
Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation
A Phase 2/3 study testing Recombinant erythropoietin alpha (rHuEPO alpha) in people with Kidney Transplantation, run by Hannover Medical School at 1 site in Germany.
Trial summary
The hematopoetic cytokine erythropoietin (EPO) has been shown to reduce programmed cell death and tissue destruction in experimental models of acute kidney ischemia-reperfusion injury. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Kidney Transplantation
- What is being tested?
- Recombinant erythropoietin alpha (rHuEPO alpha)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 88 participants
- Where
- 1 siteGermany
- Study dates
- Feb 2007to Nov 2009
- Phase
- Phase 2/3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Signed written informed consent
- Male or female aged 18 to 70 years without restricted legal competence and being able to follow the trial instructions
- Cadaveric renal transplant, cold ischemia time below 24 h, and standard immunosuppressive regimen
- A haemoglobin level > 8 and < 14 g/dl
- Treatment with standard immunosuppression (steroids, cyclosporine A, tacrolimus, MMF or azathioprine)
- In patient with diabetes mellitus HbA1c < 9%
Who cannot join
- Previous or current myelodysplastic or -proliferative disorders
- History of cancer within the last 5 years.
- Systemic chemotherapy or radiotherapy
- Higher degree renal anemia or persistent Hb > 14 g/dl
- Treatment with other stem cell growth factors cells like GM-CSF, VEGF
- Bleeding episodes within 3 month prior transplantation
Show all 19Show fewer
- Sitting diastolic BP > 110 mmHg or sitting systolic BP > 170 mmHg
- Known intolerance of rHuEpo or analogs
- Cardiovascular event within 6 months prior transplantation
- Thromboembolic event within 6 months prior transplantation
- Relevant stenosis of extra- and intracranial, and peripheral arteries
- Systemic diseases (SLE or vasculitis)
- Acute or chronic infection and/or CRP > 10 mg/l prior transplantation
- Hemolysis or disorders of blood formation (e.g., thalassemia)
- Further organ transplants or combined organ transplantation
- Pregnancy or inadequate contraception
- Psychiatric or emotional problems, or chronic seizures
- Unwillingness to participate satisfactorily for the entire trial period
- Participation in a clinical trial within 30 days prior to study inclusion
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Erythropoietin on Renal Function After Kidney Transplantation
The hematopoetic cytokine erythropoietin (EPO) has been shown to reduce programmed cell death and tissue destruction in experimental models of acute kidney ischemia-reperfusion injury. Thus, treatment with high dose recombinant human EPO (rHuEPO) may prevent kidney tissue damage and loss of renal function after successful kidney transplantation in humans.
Read the detailed description
Erythropoietin (EPO) has pleiotropic effects well beyond the maintenance of red blood cell mass. In the embryo, EPO is a major regulator of vascular formation and organ growth, and EPO receptors are found in almost every embryonic tissue. EPO receptors also exist in many adult tissues including renal tissue, and even the notion of autocrine or paracrine EPO systems has been raised. Although the peritubular fibroblasts are the major adult site for EPO production, EPO receptors have been demonstrated in many kidney cell types, e.g. proximal tubule epithelial cells, mesangial cells, and the glomerulus. Moreover, EPO has important cytoprotective effects on various cell lines and organs, and protection from ischemic injury and inhibition of apoptotic death-related pathways has been reported in brain, heart and renal tissue. The intracellular pathways involved in these favourable EPO effects may involve nuclear translocation of the transcription factor NF- B, JAK2 phosphorylation and phosphorylation of Akt (protein kinase B).
A recent experimental study revealed that cobalt administration to rats caused up-regulation of EPO, and diminished the degree of renal injury caused by ischemia-reperfusion (I/R), suggesting that EPO may also play an important role in renal ischemic preconditioning. Indeed, subsequent studies from different laboratories demonstrated that preconditioning with recombinant human EPO (rHuEPO) is protective against I/R injury in rodents. In this respect data on specific protective effects of rHuEPO and its analogues on endothelial cells of glomeruli are of particular interest. Furthermore, administration of rHuEPO may not have only protective effects on the vascular level, but also potential of regeneration, since EPO also stimulates proliferation and differentiation of regenerative cells such as endothelial progenitor cells (EPCs).
Renal ischemia, whether caused by shock or after surgery, is a major cause of acute renal failure (ARF) in man. In this respect kidney transplantation is a classical model of ARF due to I/R injury, since the transplanted organ is connected to the recipients blood supply usually after several hours of "cold ischemia". Although reperfusion is essential for the survival of ischemic tissue, it also initiates a complex and interrelated sequence of events that results in injury and the eventual death of renal cells as a result of a combination of both apoptosis and necrosis. Apoptotic cell death has been documented in human biopsies after renal I/R, and inhibition of apoptotic signalling and cell death ameliorates the associated injury and inflammation in an experimental model of ischemic ARF. Similarly, I/R damage of transplanted kidney is thought to be a major factor limiting renal function after successful transplantation.
- Conditions
- Kidney Transplantation
- Being tested
- Recombinant erythropoietin alpha (rHuEPO alpha), Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Recombinant erythropoietin alpha (rHuEPO alpha)Drug
Also called Erypo
Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
PlaceboDrug
Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
| Study group | Role | What they receive |
|---|---|---|
| intravenous erythropoietin | Active comparator | Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation Receives: Drug: Recombinant erythropoietin alpha (rHuEPO alpha); Drug: Placebo |
| intravenous placebo | Placebo comparator | Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR)
Estimated glomerular filtration rate (eGFR) was assessed using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)equation
Measured: 42 days after transplantation
Secondary outcomes (1)
Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR)
Estimated glomerular filtration rate (eGFR) was assessed using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)equation
Measured: 6 month after transplantation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2007 (estimated)
- Study startFeb 2007
- Primary completionMay 2009
- Study completionNov 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Kidney TransplantationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 88 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hannover Medical School
- Sponsor type
- University, hospital or other
- Investigators
- Danilo Fliser, MD, Principal investigator, Saarland University Medical Centre
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00425698
- Sponsor's protocol ID
- MHH - EPONTX - 01/06
- Status last verified
- Sep 2010
- First submitted
- 22 Jan 2007
- Last updated
- 28 Sep 2010
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 28 Sep 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Erythropoietin on Renal Function After Kidney Transplantation
- ClinicalTrials.gov ID
- NCT00425698
- Acronym / sponsor ID
- MHH - EPONTX - 01/06
- Conditions
- Kidney Transplantation
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 88 participants (actual)
- Lead sponsor
- Hannover Medical SchoolUniversity, hospital or other
- Study start
- Feb 2007
- Primary completion
- May 2009 (actual)
- Study completion
- Nov 2009 (actual)
- First posted
- 23 Jan 2007 (estimated)
- Results
- Posted 23 Sep 2010
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The hematopoetic cytokine erythropoietin (EPO) has been shown to reduce programmed cell death and tissue destruction in experimental models of acute kidney ischemia-reperfusion injury. Thus, treatment with high dose recombinant human EPO (rHuEPO) may prevent kidney tissue damage and loss of renal function after successful kidney transplantation in humans.
Detailed description
Erythropoietin (EPO) has pleiotropic effects well beyond the maintenance of red blood cell mass. In the embryo, EPO is a major regulator of vascular formation and organ growth, and EPO receptors are found in almost every embryonic tissue. EPO receptors also exist in many adult tissues including renal tissue, and even the notion of autocrine or paracrine EPO systems has been raised. Although the peritubular fibroblasts are the major adult site for EPO production, EPO receptors have been demonstrated in many kidney cell types, e.g. proximal tubule epithelial cells, mesangial cells, and the glomerulus. Moreover, EPO has important cytoprotective effects on various cell lines and organs, and protection from ischemic injury and inhibition of apoptotic death-related pathways has been reported in brain, heart and renal tissue. The intracellular pathways involved in these favourable EPO effects may involve nuclear translocation of the transcription factor NF- B, JAK2 phosphorylation and phosphorylation of Akt (protein kinase B).
A recent experimental study revealed that cobalt administration to rats caused up-regulation of EPO, and diminished the degree of renal injury caused by ischemia-reperfusion (I/R), suggesting that EPO may also play an important role in renal ischemic preconditioning. Indeed, subsequent studies from different laboratories demonstrated that preconditioning with recombinant human EPO (rHuEPO) is protective against I/R injury in rodents. In this respect data on specific protective effects of rHuEPO and its analogues on endothelial cells of glomeruli are of particular interest. Furthermore, administration of rHuEPO may not have only protective effects on the vascular level, but also potential of regeneration, since EPO also stimulates proliferation and differentiation of regenerative cells such as endothelial progenitor cells (EPCs).
Renal ischemia, whether caused by shock or after surgery, is a major cause of acute renal failure (ARF) in man. In this respect kidney transplantation is a classical model of ARF due to I/R injury, since the transplanted organ is connected to the recipients blood supply usually after several hours of "cold ischemia". Although reperfusion is essential for the survival of ischemic tissue, it also initiates a complex and interrelated sequence of events that results in injury and the eventual death of renal cells as a result of a combination of both apoptosis and necrosis. Apoptotic cell death has been documented in human biopsies after renal I/R, and inhibition of apoptotic signalling and cell death ameliorates the associated injury and inflammation in an experimental model of ischemic ARF. Similarly, I/R damage of transplanted kidney is thought to be a major factor limiting renal function after successful transplantation.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| intravenous erythropoietin | Active comparator | Drug: Recombinant erythropoietin alpha (rHuEPO alpha), Drug: PlaceboErythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation |
| intravenous placebo | Placebo comparator | Drug: PlaceboPlacebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Signed written informed consent
- Male or female aged 18 to 70 years without restricted legal competence and being able to follow the trial instructions
- Cadaveric renal transplant, cold ischemia time below 24 h, and standard immunosuppressive regimen
- A haemoglobin level > 8 and < 14 g/dl
- Treatment with standard immunosuppression (steroids, cyclosporine A, tacrolimus, MMF or azathioprine)
Key exclusion criteria (19 listed)
- Previous or current myelodysplastic or -proliferative disorders
- History of cancer within the last 5 years.
- Systemic chemotherapy or radiotherapy
- Higher degree renal anemia or persistent Hb > 14 g/dl
- Treatment with other stem cell growth factors cells like GM-CSF, VEGF
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Recombinant erythropoietin alpha (rHuEPO alpha)Also: ErypoErythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation | Drug | intravenous erythropoietin |
| PlaceboPlacebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation | Drug | intravenous erythropoietin, intravenous placebo |
Primary outcome
Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR)
Time frame: 42 days after transplantation
Estimated glomerular filtration rate (eGFR) was assessed using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)equation
1 secondary outcome
Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR)
Time frame: 6 month after transplantation
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Sep 2010.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Kidney Transplantation
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
RecruitingPhase 2
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
Antibody-Mediated Rejection (AMR)
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Not yet recruitingEarly Phase 1
Biomarker-Guided Mycophenolate Mofetil Elimination in Low-Risk Older Adult Kidney Transplant Recipients
Kidney Transplant Recipient
Recruiting
Non-Invasive Monitoring of Pediatric Kidney Transplant Recipients and Immunosuppression Personalization: an Open-labeled Multicenter Randomized Controlled Study
Pediatric Kidney Disease, Transplant;Failure,Kidney
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Danilo Fliser, MD principal investigator
Saarland University Medical Centre
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Recombinant erythropoietin alpha (rHuEPO alpha) in people with Kidney Transplantation, run by Hannover Medical School at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Sep 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 23 Sep 2010). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR) (time frame: 42 days after transplantation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2010.